Measured by its ability to induce osteoclast differentiation of RAW 264.7 mouse monocyte/macrophage cells. The EC50 for this effect is less than 1ng/ml.
Product Details
Product Details
Product Specification
Species | Human |
Synonyms | Tumor necrosis factor ligand superfamily member 11; Osteoclast differentiation factor (ODF); Osteoprotegerin ligand (OPGL); Receptor activator of nuclear factor kappa-B ligand (RANKL); TNF-related activation-induced cytokine (TRANCE); |
Accession | O14788 |
Amino Acid Sequence | Ile140-Asp317 |
Expression System | E.coli |
Molecular Weight | 21 kDa (Reducing) |
Purity | >95% by SDS-PAGE and HPLC. |
Endotoxin | <0.1EU/μg |
Conjugation | Unconjugated |
Tag | No Tag |
Physical Appearance | Lyophilized Powder |
Storage Buffer | 20mM Sodium Citrate, pH 5.0 |
Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
Stability & Storage | ·12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
Reference | Cell. 2000 Sep 29;103(1):41-50. |
Background
Receptor activator of nuclear factor kappa-B ligand (RANKL), also known as TNF-related activation-induced cytokine (TRANCE), is a cytokine that belongs to the tumor necrosis factor (TNF) superfamily. In humans, RANKL is primarily expressed by osteoblasts, T cells, and other immune cells, and plays a crucial role in regulating bone metabolism, immune function, and the development of mammary glands. RANKL functions by binding to its receptor RANK on the surface of osteoclast precursors, leading to the activation and differentiation of osteoclasts, which are responsible for bone resorption. Additionally, RANKL is involved in the regulation of T cell activation, dendritic cell function, and the formation of lactating mammary glands. Dysregulation of RANKL has been implicated in various bone-related diseases, such as osteoporosis and bone metastasis, as well as in immune disorders, highlighting the importance of RANKL in skeletal biology and immune regulation.
Picture
Picture
Bioactivity
SDS-PAGE
2μg (R: reducing condition, N: non-reducing condition).
SEC-HPLC
>95% as determined by SEC-HPLC.
